tbuckley/cabot-search huggingface dataset:
AB0126 Comparison of Serum Apelin, Fetuin-A Levels and Carotid Intima-Media Thickness in Patients with Sjögren's Syndrome and Healthy Subjects
Authors: A. Şahin, D. Seven, Ö. Demirpençe, D. Seven, A. Camcı
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Apelin is a glycoprotein, adipocytokine that plays an important role in decreasing the vascular inflammation on cardiovascular and metabolic disorders (1). Fetuin-A is also another glycoprotein that can be an acute phase protein negatively correlates with inflammation (2). Carotid intima-media thickness (C-IMT) may indicate vascular inflammation in primary Sjögren9s syndrome (3). However, we do not know the relationship between serum apelin, fetuin-a levels and C-IMT in patients with Sjögren9s syndrome. <h3>Objectives</h3> To compare of the serum Apelin, Fetuin-A levels and C-IMT in patients with Sjögren9s syndrome (SjS) and healthy controls. <h3>Methods</h3> Sixty-SjS patients and sixty healthy subjects were enrolled to this study. Serum apelin, fetuin-a levels were measured by ELISA. Concomitant C-IMT evaluations of the participants were performed. The BMI, insulin, HOMA-IR, lipid profiles were studied. Other laboratory parameters, autoantibody profiles, minor salivary gland biopsy scores (Chisholm) were obtained from patient9s record files. The study was approved by the local ethics committee. <h3>Results</h3> The median levels of apelin were 178.02±55.23 ng/mL in healthy subjects and 98.66±37.25 ng/mL in SjS (p&lt;0.05) (Figure 1). The median levels of fetuin-a were 1370.3±81.74 ng/mL in control group and 1613±64.49 ng/mL in SjS group (p=0.021) (Figure 1). The C-IMT was negatively correlated with apelin levels in SjS patients (r= - 0.209, p=0.02). There was no significant correlation between fetuin-a levels and C-IMT in SjS (p=0.08). However, there were significant correletions between C-IMT and hemoglobin-A1c (r=0.353, p=0.005), C3 (r=0.36, p=0.004), C4 (r=0.351, p=0.005). <h3>Conclusions</h3> We found lower serum apelin and higher fetuin-a levels in SjS patients than in healthy subjects. Apelin and fetuin-a may be a new possible surrogate biomarker of inflammation in Sjögren9s syndrome. <h3>References</h3> Gualillo O, Gonzalez-Juanatey JR, Lago F. The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. Trends Cardiovasc Med 2007 Nov;17(8):275–83. Harman H, Tekeoğlu İ, Gürol G, et al. Comparison of fetuin-A and transforming growth factor beta 1 levels in patients with spondyloarthropathies and rheumatoid arthritis. Int J Rheum Dis. 2016 Jan 22. doi: 10.1111/1756-185X.12791. [Epub ahead of print]. Gravani F, Papadaki I, Antypa E, et al. Subclinical atherosclerosis and impaired bone health in patients with primary Sjogren9s syndrome: prevalence, clinical and laboratory associations. Arthritis Res Ther 2015 Apr 11;17:99. doi: 10.1186/s13075-015-0613-6. <h3>Acknowledgement</h3> We would like to thank to "Cumhuriyet University Scientific Researches Project Unit (CUBAP)" for funding this project. <h3>Disclosure of Interest</h3> None declared
Direct and Coordinate Regulation of Multidrug Resistance Genes by the c-Myc Oncoprotein.
Authors: Antonio Porro, Simona Soverini, Daniel Diolaiti, Tiziana Grafone, Emanuela Ottaviani, Nunzio Iraci, Carolina Terragna, Thea Kalebic, Michele Baccarani, Giovanni Martinelli, Giuliano Della Valle, Giovanni Perini
Journal: Blood (2006)
Cyclin D1 C.870G&gt;a Polymorphism in Patients with Multiple Myeloma after Allogeneic Stem Cells Transplantation
Authors: Olga Blau, Ekaterina Slonova, Rimma Berenstein, Axel Nogai, Kathrin Rieger, Antonio Pezzutto, Bernd Dörken, Igor Wolfgang Blau
Journal: Blood (2014)
THU0103 Is Interleukin 17 Implicated in Osteoporosis Pathogenesis in Rheumatoid Arthritis? Relation between IL-17 Serum Level and Frax Index in Premenopausal Rheumatoid Arthritis Patients
Authors: N.A. Aboeladl, H.K. Koryem, M.A. Rezk, M.M. Hassan, S.S. Eltawab
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis (RA) is one of the most common form of inflammatory arthritis. It is characterized by being chronic, progressive with systemic inflammation. Patients with RA are at an increased risk of osteoporosis (OP) and consequentaly osteoporotic fractures (OFs). Interleukin-17 (IL-17) is a cytokine expressed in inflammatory and autoimmune diseases. It plays an important role in the pathogenesis of RA and OP. Fracture Risk Assessment Tool (FRAX)is a computer-based algorithm used to measure the 10-year probability of a major osteoporotic fractures and the 10-year probability of hip fracture. Current studies focus on better assessment of risk factors of OFs in RA patients aiming to prevent them and their subsequent complications. <h3>Objectives</h3> To study the correlation between serum IL-17 level and FRAX index scores in pre-menopausal RA patients. <h3>Methods</h3> This study included 25 premenopausal RA patients and 20 healthy controls. Serum IL-17 level was measured by using ELISA technique, bone mineral density (BMD) measured using DEXA scan and FRAX index was calculated by using online FRAX calculator (Femoral neck BMD was used to enhance fracture risk prediction). <h3>Results</h3> Serum IL-17 level among RA patients was significantly higher than healthy controls, (5.99 ± 1.22pg/ml), (3.73 ± 2.15pg/ml) respectively with a <i>p</i>&lt;0.001. Serum IL-17 levels showed a positive significant correlation with the FRAX index scores in RA patients. <h3>Conclusions</h3> IL-17 is highly suspected to be implicated in the pathogenesis of OP in RA patients which may spotlight that the emergence of IL 17 blockade as a future therapy in RA is to be highlighted. <h3>References</h3> Kim SY, Schneeweiss S, Liu J, Daniel GW, Chang C-L, Garneau K, et al. Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. Arthritis Research &amp; Therapy 2010; 12(4):R154. Sorbi R, Aghamirsalim M. Osteoporotic Fracture Program management: Who should be in charge? A comparative survey of knowledge in orthopaedic surgeons and internists. Orthop Traumatol Surg Res 2013; 99(6):723–30. Rosu A, Margaritescu C, Stepan A, Musetescu A, Ene M. IL-17 patterns in synovium, serum and synovial fluid from treatment-naive, early rheumatoid arthritis patients. Rom J Morphol Embryol 2012; 53(1):73–80. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey EV.FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008; 19:385–97. <h3>Acknowledgement</h3> Deep thanks to my professors, parents and my husband <h3>Disclosure of Interest</h3> None declared
Prognostic Impact of EZH2 and ASXL1 Mutation in Myelofibrosis
Authors: Paola Guglielmelli, Flavia Biamonte, Johannah Score, Claire Hidalgo-Curtis, Francisco Cervantes, Margherita Maffioli, Tiziana Fanelli, Thomas Ernst, Nils Winkelman, Amy V Jones, Katerina Zoi, Andreas Reiter, Andrew Duncombe, Laura Villani, Chiara Paoli, Alberto Bosi, Giovanni Barosi, Nicholas C.P. Cross, Alessandro M. Vannucchi
Journal: Blood (2011)
Gradients of the signaling lipid S1P in lymph nodes position natural killer cells and regulate their interferon-γ response
Authors: Victoria Fang, V Sai Chaluvadi, Willy D Ramos-Perez, Alejandra Mendoza, Audrey Baeyens, Richard Rivera, Jerold Chun, Michael Cammer, Susan R Schwab
Journal: Nature Immunology (2016)
Statins for Primary Prevention
Authors: Rita F. Redberg, Mitchell H. Katz
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients.
Authors: Alex Bazeos, Jamshid Khorashad, François-Xavier Mahon, Lina L Eliasson, Dragana Milojkovic, Marco Bua, Jane Apperley, Richard Szydlo, Kasia Kozlowski, Christos Paliompeis, Ritti Desai, Letizia Foroni, Alistair Reid, Hugues de Lavallade, Katy Rezvani, John Goldman, David Marin
Journal: Blood (2009)
Detection of Genomic Lesions in Childhood Precursor-B Cell ALL in Diagnosis and Relapse Samples Using High Resolution Genomic Profiling.
Authors: Roland P. Kuiper, Frank N. van Leeuwen, Suzanne T.M. Keijzers-Vloet, Simon V. van Reijmersdal, Jayne Y. Hehir-Kwa, Elisabeth R. van Wering, Vincent H.J. van der Velden, Jacques J.M. van Dongen, Eric F.P.M. Schoenmakers, Ad Geurts van Kessel, Peter M. Hoogerbrugge
Journal: Blood (2007)
The Superior Prognosis of Female Patients with Hodgkin’s Lymphoma Is Related to More Treatment-Induced Leucopenia and Warrants a More Individualized Therapy.
Authors: Beate Klimm, Thorsten Reineke, Heinz Haverkamp, Hans T. Eich, Andreas Josting, Beate Pfistner, Volker Diehl, Andreas Engert
Journal: Blood (2004)
Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.
Authors: Irene M. Ghobrial, Renee Leduc, Marybeth Nelson, Xavier Leleu, Eric Jacobsen, Ann LaCasce, Daniel DeAngelo, David Fisher, Jennifer R. Brown, Robert Schlossman, Diane Warren, Jacob Soumerai, Kelly O’Connor, Nikhil Munshi, Paul Richardson, Kenneth C. Anderson, Thomas E. Witzig, Steven P. Treon
Journal: Blood (2007)
Allogeniec Stem Cell Transplantation for Primary and Post ET/PV Myelofibrosis At Mayo Clinic: A Retrospective Review Across a Geographically Diverse 3 Site Cancer Center.
Authors: Veena Devi Salem Fauble, James L Slack, William Hogan, Vivek Roy, Jose Leis, Amylou C. Dueck, Mark R Litzow, Mrinal M. Patnaik, Pardanani Animesh, Candido E. Rivera, Raoul Tibes, John Camoriano, Roberta H. Adams, Pierre Noel, Nandita Khera, Lisa Sproat, Ruben A. Mesa
Journal: Blood (2012)
Non Invasive Assessment of Hepatic Fibrosis by Measurement of Liver Stiffness in Post Transfusional Iron Overload: Preliminary Results in 15 Patients.
Authors: T. Mirault, D. Lucidarme, B. Turlin, Y. Deugnier, P. Brissot, K. Kanaan, J.L. Demory, P. Gosset, P. Vandevenne, A. Charpentier, O. Ernst, Christian Rose
Journal: Blood (2006)
Risk Factors for Venous Ulcer Following ACUTE Venous Thromboembolism: Results from the Riete Registry
Authors: Jean-Philippe Galanaud, Laurent Bertoletti, Paolo Prandoni, Pedro Gallego, Daniela Mastroiacovo, Lucia Mazzolai, Angel Samperiz, Yacine Rabah, Nuria Ruiz-Gimenez, Marija Zdraveska, Susan R Kahn, Manuel Monreal
Journal: Blood (2015)
Drug Delivery: Breaching the Hyaluronan Barrier with PH20-Fc Facilitates Intratumoral Permeation and Enhances Antitumor Efficiency: A Comparative Investigation of Typical Therapeutic Agents in Different Nanoscales (Adv. Healthcare Mater. 22/2016)
Authors: Shan Liu, Wei Wei, Bo Xie, Hua Yue, Dezhi Ni, Yali Bao, Guanghui Ma, Zhiguo G. Su
Journal: Advanced Healthcare Materials (2016)

On page 2872, Guanghui Ma, Zhiguo Su, and co-workers construct a long-acting hyaluronidase (PH20-Fc) as a diffusion facilitator for typical anticancer agents: doxorubicin, trastuzumab, and gold nanorod. Although effective, the performances vary among these therapeutic agents. Trastuzumab benefits most from PH20-Fc with a best improvement in penetration and accumulation. Their systematic investigations thus reveal the importance of therapeutics size effect when using diffusion facilitator for anticancer therapy.
Refining the Understanding of the Effects of Prenatal Methamphetamine and Tobacco Exposure on the Developing Brain
Authors: Annerine Roos, Kirsten Ann Donald
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Reduced Intensity Stem Cell Transplantation and Donor Lymphocyte Infusion after Imatinib Induction To Eradicate Residual Disease in Chronic Myeloid Leukaemia.
Authors: Nicholas Heaney, Mhairi Copland, Karen Stewart, Judith Godden, Anne Parker, Grant McQuaker, Graeme Smith, Charles Crawley, Pat Shepherd, Tessa L. Holyoake
Journal: Blood (2007)
Unraveling The Molecular and Metabolic Basis For Glutamine Addiction In Leukemias
Authors: Polina Matre, Ismael Samudio, Rodrigo Jacamo, Ying Wang, Jing Wang, R Eric Davis, Xiaohua Su, Sonja Schindela, Rachel Newman, Jianhua Hu, Torsten Haferlach, Michael Andreeff, Elsa R. Flores, Aaron Schimmer, Marina Konopleva
Journal: Blood (2013)
Phase II Randomized, Multicenter Study of Lenalidomide Vs Best Investigator’s Choice in Relapsed/Refractory Mantle Cell Lymphoma: Results of the MCL-002 (SPRINT) Study
Authors: Marek Trneny, Thierry Lamy, Jan Walewski, Wojciech Jurczak, David Belada, Jiri Mayer, John Radford, Julia Alexeeva, Dzhelil Osmanov, Tsvetan Biyukov, Meera Patturajan, Marie-Laure Casadebaig Bravo, Luca Arcaini
Journal: Blood (2014)
The Decision to Limit or Withdraw Specific Therapies for Advanced Cancer and Hematological Malignancies: Physicians and Patients Points of View and Interactions.
Authors: Yvan Beaussant, Lionel Pazart, Christophe Tournigand, Florence Mathieu-Nicot, Elodie Cretin, Eric Deconinck, Régis Aubry
Journal: Blood (2011)
Post-Transplant Donor Lymphocyte Infusion with Methotrexate Prophylaxis Is Associated with Low Incidence of Relapse after CD34-Selected, T Cell-Depleted Haploidentical Donor Stem Cell Transplantation Regardless of NK Alloreactivity
Authors: Michael J Eckrich, Stacy Epstein, Carrie Barnhart, Javier Oesterheld, Darci Grochowski, Mark Cannon, Andrew L Gilman
Journal: Blood (2015)
Clinical Significance of Serum Concentration of L-Kynurenine for T-Cell Lymphoma Treated with CHOP
Authors: Nobuhiro Kanemura, Hisashi Tsurumi, Junji Nagano, Takeshi Hara, Kengo Ogawa, Soranobu Ninomiya, Naoe Goto, Senji Kasahara, Hisataka Moriwaki
Journal: Blood (2011)
The Cytofluorimetric/FISH Diagnostic Approach Define a B-Cell Variant-CLL with Peculiar Clinico-Biological Features.
Authors: Lilla Cro, Luca Baldini, Lucia Nobili, Antonino Neri, Nadia Zucal, Andrea Ferrario, Marta Lionetti, Francesco Bertoni, Fortunato Morabito, Andrea Guffanti, Maria Goldaniga, Giovanna Cutrona, Agostino Cortelezzi, Stefano Luminari8, Manlio Ferrarini, Giorgio Lambertenghi Deliliers
Journal: Blood (2007)
AB0102 Iguratimod (T-614) Suppresses Rankl-Induced Osteoclast Differentiation and Migration in RAW264.7 Cells via NF-κB and MAPK Pathways
Authors: K. Gan, L. Yang, W. Tan, M. Zhang
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Iguratimod (T-614) has been confirmed as a highly efficacious and safe novel disease-modifying anti-rheumatic drug (DMARDs) for rheumatoid arthritis therapy in China and Japan due to its potent anti-inflammation effect. <h3>Objectives</h3> Here, we investigate the effects of lguratimod on osteoclast differentiation, migration and function. <h3>Methods</h3> The effect of Iguratimod on osteoclastogenesis, migration and bone resorption were assessed by TRAP staining, transwell migration assay and osteologic discs, respectively. Relative expressions of osteoclastic related genes, chemokines and transcription factors were assessed by reverse transcription polymerase chain reaction (RT-PCR) and signaling pathways were analyzed by western blotting. <h3>Results</h3> Iguratimod significantly inhibits osteoclast differentiation, migration and bone resorption in RANKL-induced RAW264.7 cell in a dose-dependent manner. The expressions of osteoclastic related genes including TRAP, CTSK and CTR were increased in RAW264.7 cell upon RANKL stimulation but were obviously suppressed in the presence of Iguratimod. RANKL induced the expression of chemokines including CCL7, CCL4 and CCL12 and osteoclastic related transcription factors of c-Fos, c-JUN and NFATc1 could be significantly inhibited by Iguratimod in a dose dependent manner. Western blotting indicated Iguratimod could suppress the activation of MAPKs and NF-κB pathway in RANKL induced osteoclastogenesis in RAW264.7. <h3>Conclusions</h3> These findings revealed a directly inhibitory role of Iguratimod on osteoclast formation and function, which is distinct from previous report, suggesting Iguratimod provide a unique therapeutic strategy for RA and especially in light of preventing bone destruction. <h3>Disclosure of Interest</h3> None declared
SNP Array Analysis in Acute Myeloid Leukemia Reveals Frequent and Recurrent Acquired Genetic Alterations Linked to Prognosis: a Study of the ALFA Group
Authors: Olivier Nibourel, Christophe Roumier, Samuel Quentin, Sandrine Geffroy, Antonio Alberdi, Aline Renneville, Céline Berthon, Celine Villenet, Martin Figeac, Herve Dombret, Jean Soulier, Claude Preudhomme, Meyling Cheok
Journal: Blood (2011)
OC-019 Iron Deficiency Anaemia and Hepcidin Levels in H. Pylori Infected Patients
Authors: JR White, HO Al-Hassi, D Reddiar, M Mangalika, D Cvijan, Y Falcone, N Worton, M Lingaya, A Figgins, P Kaye, K Ragunath, JC Atherton, K Robinson, MJ Brookes
Journal: Gut (2016)

<h3>Introduction</h3> IDA affects up to 5% of the adult population in the developing world. There is an association between <i>H. pylori</i> (Hp) infection and incidence of unexplained IDA, but the mechanisms remain unclear. In children it has been suggested that Hp disturbs the iron regulatory mechanism via hepicidin. This peptide hormone induces internalisation and degradation of the iron transporter protein ferroportin thus limiting iron absorption and release. Hepcidin expression is induced by inflammation, but how this relates to Hp and IDA has not been fully elucidated, particularly in adults. This pilot study aimed to characterise local and systemic iron transporter expression in IDA patients with and without Hp infection, in comparison to Hp negative dyspepsia controls. <h3>Methods</h3> Patients undergoing routine endoscopy for IDA (HpIDA and IDA groups, n = 18 and 40 respectively) or without IDA (control group, n = 18) donated blood and biopsy samples with informed consent and ethical approval. Hp status was assessed by three biopsy based tests and by serology. Duodenal and gastric biopsies were evaluated by immunohistochemistry for ferroportin and hepcidin, in addition to H&amp;E staining for inflammation and atrophy grading. All scoring was carried out by experienced blinded histopathologists. A commercial ELISA assay was used to quantify serum Hepcidin-25. <h3>Results</h3> As expected, anaemia parameters were significantly lower in the HpIDA and IDA groups compared to the controls (P &lt; 0.0001). Surprisingly, serum hepcidin concentrations were significantly reduced in the HpIDA and IDA groups compared to the controls (9 fold, P = 0.009 and 5 fold, P &lt; 0.0001 respectively). Hp infection was associated with gastric expression of hepcidin, particularly in the corpus when compared to controls. This corresponded with the cytoplasmic relocalisation of ferroportin (n = 12; 67%) in the duodenal enterocytes of patients with HpIDA compared to controls, where the ferroportin was actively expressed. Hepcidin was also found to be expressed in the duodenum of both controls and HpIDA. Significant atrophy was observed in both IDA groups. <h3>Conclusion</h3> IDA was associated with significantly lower levels of serum hepcidin in contrast to previous studies. Local or systemic factors such as inflammatory mediators could be driving this response as more severe atrophy was observed in both IDA groups. We now aim to perform quantitative analysis of hepcidin in the gastric specimens using RT-qPCR to further evaluate whether local Hp transcriptionally upregulated hepcidin expression might cause these effects on iron transport. <h3>Disclosure of Interest</h3> None Declared